Sequential isolates of human immunodeficiency virus type 1 (HIV-1) were obtained from patients with AIDS on short and long term treatment with zidovudine (3'-azido-3'-deoxythymidine; AZT). The isolates were tested for resistance to zidovudine by monitoring the inhibition of syncytium formation, HIV-l-specific immunofluorescence and p24 production in C8166 cells. The reverse transcriptase (RT) genes of zidovudinesensitive (< 1 ~tM) and -resistant (10 to 15 ~tM) strains were amplified using the polymerase chain reaction and the products were sequenced directly. The predicted amino acid sequences of the RTs ofzidovudine-sensitive and-resistant isolates showed 95 to 97 % identity to the corresponding sequence of HIV-lsr 2 which was used as a reference. Amino acid changes at positions 41, 67, 70, 215 and 219 which are known to be associated with zidovudine resistance were present in some, but not all isolates exhibiting zidovudine resistance in vitro. This indicates that mutations in the RT of HIV-1, other than those already identified, may be involved in conferring resistance to zidovudine.
Introduction
Zidovudine (3'-azido-3'-deoxythymidine; AZT) is used extensively in the treatment of symptomatic human immunodeficiency virus (HIV) infection (Fischl et al., 1987; Mitsuya et al., 1985) . This drug is a thymidine analogue which diffuses passively into cells (Zimmerman et al., 1987) where it is converted to the 5'-monophosphate form by cellular thymidine kinases. Thymidylate kinases further phosphorylate zidovudine monophosphate to the di-and triphosphate forms (Furman et al., 1986) . The activated drug acts as a competitive inhibitor of HIV reverse transcriptase (RT), being incorporated into viral DNA in place of TTP (Mitsuya et al., 1985) . Since the 3' hydroxyl group has been replaced by an azido group, elongation of viral DNA is terminated at the point of incorporation.
Prolonged zidovudine therapy is associated with reduced in vitro sensitivity of HIV-1 isolates (Rooke et aI., 1989; Boucher et al., 1990) . HIV isolates from patients treated for less than 6 months were found to be indistinguishable in sensitivity compared to isolates from untreated individuals. However, after 6 months of treatment a reduction in sensitivity was observed . Specific amino acid changes encoded by the RT gene were found to be associated with this phenotype (Met-41 -> Leu, Asp-67-+ Asn, Lys-70 + Arg, Thr-215 + Tyr/Phe, Lys-219-+ Arg) (Larder & Kemp, 1989) . Infectious HIV cDNA clones were constructed containing these mutations and the resulting viruses were found to be resistant to zidovudine. The relative contributions of each of these mutations and of combinations were evaluated. It was found that HIV variants containing single amino acid changes at codons 70 or 215 were partially resistant to zidovudine. Those containing single substitutions at codons 67 and 219 showed no decrease in sensitivity, but these changes may contribute to the overall phenotype .
In this paper we describe the isolation of zidovudinesensitive and -resistant HIV isolates. Sequence analysis of RTs of some zidovudine-resistant isolates indicated the presence of amino acid changes different from those already associated with this phenotype.
Methods
Virus isolation. HIV-1 strains were isolated from hospitalized AIDS patients or patients in outpatient care at East Birmingham Hospital. All patients were at CDC stage IV; most had very low CD4 cell numbers when they entered the study and were receiving doses of between 1250 and 300 mg zidovudine per day (Table 1) . The patients complied well with the treatment. Patients' lymphocytes were cocultivated with phytohaemagglutinin-stimulated (10 I~g/ml) cord blood * Endpoint dilutions of cell-free supernatants were used to infect C8166 cells in the presence of 0 to 15 ~tM-zidovudine. The ability of zidovudine to inhibit syncytium formation, HIV-specific immunofluorescence and p24 production was used to determine its sensitivity; -indicates no growth; + indicates growth at given concentration. t ND, Not done. :~ This patient had received zidovudine for 12 months and was then placed on ddI four months later. The patient had received ddI for 1 month when this blood sample was obtained.
lymphocytes (CBLs) (Briesen et al., 1987; Ulrich et al., 1988) . Virus infection was monitored by checking syncytium formation, the production of viral antigens in cells using a monospecific anti-gp120 antibody raised in sheep (Sigma) and fluorescein isothiocyanateconjugated anti-sheep antibody (Sigma), and p24 production using a commercial kit (Coulter). Cell-free supernatant from positive CBL cultures was used to infect the continuous cell line C8166.
Zidovudine sensitivity assay. Cell-free supernatants of syncytiumforming and p24-positive C8166 cultures were titrated and the endpoint dilutions used to reinfect C8166 cell cultures in the presence of 0 to 15 gM-zidovudine. This procedure was adopted to prevent the possibility of helper functions being exerted by resistant strains on sensitive strains in the event of several virus variants coinfecting one cell. The ability of zidovudine to inhibit syncytium formation, HIV-specific immunofluorescence and p24 production was used to determine sensitivity to the drug. Zidovudine-sensitive HIV isolates from patients who were not treated with the drug and zidovudine-resistant HIV strains A012 and A018 ; obtained through the AIDS Reagent Project) were used as controls.
Polymerase chain reaction (PCR). PCR, using nested primers, was
used to amplify the full-length RT genes from zidovudine-sensitive and -resistant isolates. DNA was extracted from syncytium-positive cultures grown in the presence of 0 to 15 gM-zidovudine. Cells were disrupted by lysis in 0-4% SDS, 25 mM-EDTA, 150 mM-NaC1 and 25 mM-Tris-HC1 pH 8, containing proteinase K (1 mg/ml). Following incubation at 65 °C for 2 h, the DNA was extracted with phenol/chloroform and precipitated with ethanol. Nested primer PCR reactions were used to amplify the fnll-length RT gene. This amplification was performed in two stages using outer followed by inner primer pairs as follows: (i) outer primers: 1877 5' GTT GAC TCA GAT TGG TTG CAC 3' 1897 (sense), 4047 5' TAG ATT CTA CTA CTC CTT GAC 3' 4027 (antisense) and (ii) inner primers: 1947 5' CCA GGA ATG GAT GGC CCA 3' 1964 (sense), 4016 5' TAG GGA ATT CCA AAT TCC TGC T 3' 3994 (antisense) (Ratner et al., 1985) . Approximately 1 gg of DNA was used as template for each PCR which contained 50 mM-KC1, 10 mM-Tris-HC1 pH 8.8, 2.0 mM-MgC12, 200 gM of each deoxynucleoside triphosphate, 1% Triton X-100 and 1 unit of Taq polymerase (Promega). The following thermal cycler programme was used: 1 min at 94 °C, 2 min at 55 °C and 3 min at 72 °C for 35 cycles. A sample from this reaction was used as template for the second reaction.
Dideoxynucleotide chain termination sequencing. PCR products were separated by electrophoresis through 1% low melting point agarose gels. Bands of the correct size were cut out and placed at 65 °C for 10 min in the presence of 20 mM-Tris-HC1 pH 8, 1 mM-EDTA. The DNA was extracted using phenol, phenol/chloroform, ether and then ethanol-precipitated. Direct sequencing of PCR products was carried out using the Sequenase version 2.0 kit (USB) according to the manufacturer's instructions with the following modifications: primer annealing reactions were carried out in the presence of 10 % DMSO (Winship, 1989) and 250 ng of ssDNA-binding protein (Promega), boiled for 2 min and snap-cooled on dry ice. One gl of 100 mM-DTT0 2 lal of labelling mix (diluted 1:4), 0.5 gl of [35S]dATP and 2 gl of Sequenase version 2.0 (diluted 1:16) were added to the annealed primer/template reaction. The reaction was allowed to proceed at room temperature for 2 min after which 3-5 gl aliquots were added to 2.5 gl of each of the termination mixes (kit) and left for a further 5 min at 37 °C. The reaction was stopped using 4 gl of stop mix containing 1 M-guanidinium isothiocyanate (BDH) which degrades the ssDNAbinding protein (added in the primer annealing step) prior to gel electrophoresis (Ball & Desselberger, 1992) . One of the outer PCR primers was used as the first sequencing primer followed by the use of the following primers, allowing the sequence of the entire RT gene to be determined: 2106 5' GAC AGT ACT AAA TGG AGA 3' 2123, 2318 5' TGA GAC ACC AGG GAT TAG ATA 3' 2338, 2467 5' TGT ATG TAG GAT CTG ACT 3" 2484, 2657 5' CAG CTG GAC TGT CAA TGA 3' 2674, 2802 5' GCA GAG CTA GAA CTG GCA GAA 3' 2822, 2983 5' GTG CCC ACA CTA ATG ATG 3' 3000, 3203 5' ACC CAT AGT AGG AGC AGA AAC 3' 3223 and 3389 5' CAT AGT AAC AGA CTC ACA 3' 3406 (Rather et al., 1985) .
Results and Discussion

Zidovudine sensitivity assay
Zidovudine resistance in vitro was found to occur in most isolates from patients who had received zidovudine for more than 5 months (Table 1 ). This is in broad agreement with observations found by other groups . However, one isolate from patient E29 who had received zidovudine for only 2 months was already resistant in vitro. Strains E26, E28 and E32 were found to be sensitive after 0, 2 and 0 months of zidovudine treatment, respectively.
Sequence variability of RTs analysed
PCR products were purified and sequenced directly, and the amino acid sequences (predicted from the nucleotide sequences) determined. The amino acid changes occurring at various positions along the RTs of zidovudinesensitive and -resistant isolates compared to the corresponding sequence of HIV-lsF 2 (Sanchez-Pescador et al., 1985) are shown in Table 2 . These data indicate that the RTs of the HIV-1 isolates analysed are highly conserved but contain some variable regions, e.g. at amino acid positions 121 to 124, 272 to 277, 292 to 299, 399 to 403 and 464 to 472. At the nucleotide level more changes were found, namely 3"5 to 4 % over a sequenced length of approximately 1700 nucleotides. Some of these changes were in the third position of coding triplets and remained silent (data not shown). The RTs of sensitive and resistant isolates showed approximately 96 % amino acid sequence identity to the RT of HIVsF 2 and the zidovudine-sensitive strains did not contain any of the amino acid changes previously associated with resistance to this drug .
Comparison of amino acid changes found in sensitive and resistant isolates
Amino acid changes were found in positions 35, 43, 102, 124, 133, 150, 254, 282, 298, 299, 445, 449, 472 and 493 of sensitive strains only and in positions 121, 122, 135, 179, 245, 267, 272, 277, 293, 297, 316, 326, 375, 376, 386, 390, 400, 403, 460, 466, 468, 469, 470 , 519 and 527 of both sensitive and resistant strains, and the latter positions may therefore be less likely to contribute to zidovudine resistance. However, amino acid changes common to sensitive and resistant strain RTs may in some way contribute to the overall phenotype and will be investigated further. Amino acid changes in zidovudineresistant strains only were found in positions 41, 60, 70, 98, 108, 123, t42, 151, 162, 172, 173, 195, 207, 211,215, 278, 281,286, 292, 311,334, 335, 360, 379, 399, 419, 464, 466, 516 and 553 . Two zidovudine-resistant isolates (E28C and E32C) contained mutations at amino acid positions 41 (Met-+Leu) and 215 (Thr-+Tyr). One isolate (E26C) was found to contain one of the published changes, at amino acid position 70 (Lys-~ Arg). Another isolate (E29D) contained only one mutation, at position 215 (Thr-+Tyr), and was found to be a zidovudineresistant (15 gM), rapidly growing virus.
Identification of RTs from zidovudine-resistant isolates without amino acid changes associated with this phenotype
Three isolates, E27A, E29 and E4A, were found to be zidovudine-resistant in vitro but did not contain any of the published amino acid changes associated with zidovudine resistance. Patient E27A had received zidovudine for 12 months and was then placed on 2',3'-dideoxyinosine (ddI) 4 months later (Yarchoan et al., 1989) . This patient had received ddI for 1 month when the blood sample analysed was obtained. It has been shown that isolates from patients who had discontinued zidovudine treatment and had begun ddI treatment were substantially more sensitive to zidovudine within 6 to 12 months of starting ddI treatment (St Clair et al., 1991) . Given the fact that this patient had received ddI for only 1 month, it was not surprising that this isolate should still be zidovudine-resistant. Patient E29 had received zidovudine for 2 months when the blood sample analysed was obtained. This isolate grew very well in the presence of 15 ~M-zidovudine. A follow-up blood sample (E29D) obtained 13 months later yielded virus that was also found to be resistant to zidovudine. Sequence data for the RT of this isolate showed the presence of one mutation at amino acid position 215 which has already been associated with zidovudine resistance (Larder & Kemp, 1989) . Patient E4A had received zidovudine for 12 months at the time when the blood sample investigated was taken. The isolate exhibited zidovudine resistance in vitro, growing in the presence of 15 ~tM-zidovudine. However, none of the published zidovudine-associated mutations were found in the RT of this isolate.
The three zidovudine-resistant strains which did not have amino acid changes in positions 41, 67, 70, 215 and 219 had novel changes in amino acid positions 108 (Val ~-Ile), 135 (Ile-~Val), 281 (Lys~Arg), 464 (Gin -+ Lys) (E29 only), 245 (Met -+ Gln), 334 (Gln-+ His), 335 (Gly-+Asp), 379 (Ser-+Gly) (E27A only) and 173 (Lys ~-Glu) (E29 and E27A). In addition, two of the three (namely E29 and E4A) had a change in amino acid position 211 (Arg-+Lys) which was also found in resistant strains E29D and E32C. Strain E4A had a single change at position 211 and thus this change, in conjunction with others common to those found in sensitive and resistant isolates, may contribute to the zidovudine resistance phenotype of this isolate. In order to confirm the correlation of these genotypes with the zidovudine resistance phenotype, isolates E29, E27A and E4A were recultured using endpoint dilutions of each and were found to be reproducibly resistant.
The crystal structure of the HIV-1 RT complexed with an inhibitor has recently been described (Kohlstaedt et al., 1992) . It was found that the two major regions where mutations render the enzyme resistant to zidovudine or ddI (amino acid positions 41 to 74 and 215 to 219; Larder & Kemp, 1989; Larder et al., 1991 ; St Clair et al., 1991) are on the 'fingers' and 'palm' subdomains of the molecule, respectively, and are likely to be involved in protein template interactions (Kohlstaedt et al., 1992) . Amino acid changes at positions 173 and 211, most suspected from our data to be additional mutations involved in zidovudine resistance, are located on the 'palm' subdomain of the HIV-1 RT molecule.
In summary, various mutations in the RT of zidovudine-resistant HIV-1 isolates have been identified Lys ---Ser ---* Isolates were grown in the presence of zidovudine. DNA was extracted from syncytium-and p24-positive cultures. The full-length RT genes were PCR-amplified and sequenced directly. The amino acid changes indicated are those compared to HIVs~2; -indicates an amino acid identical to that found in HIVsF 2.
previously by others and shown to be associated with this phenotype. In this study some of these changes were found in four zidovudine-resistant isolates. However, three other zidovudine-resistant isolates did not contain any of these but other mutations. It is intended to insert the full-length RT genes of these isolates into an infectious cDNA clone of HIV-1 in order to confirm and investigate further their zidovudine resistance.
